International
The Morning Science

What science found today

‹
 

Launch

FDA Adds Another Player in ALK-Positive Lung Cancer

MedPage Today ·

FDA Adds Another Player in ALK-Positive Lung Cancer

The Brief

  • The FDA granted accelerated approval to neladalkib, marketed as Nelkarmi, for previously treated advanced ALK-positive non-small cell lung cancer.
  • Neladalkib is a third-generation ALK inhibitor and the seventh approved agent for this cancer type, according to MedPage Today.

Why it matters

It adds another targeted option for patients with ALK-positive lung cancer whose disease has progressed after earlier treatment. Accelerated approval rests on interim evidence, so confirmatory results will matter.

Who’s affected

  • oncologists treating non-small cell lung cancer
  • patients with previously treated ALK-positive advanced lung cancer

(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...

How do you feel about this?

0 Comments

    FDA Adds Another Player in ALK-Positive Lung Cancer – The Morning Science